OUR TECHnology
Our platform is uniquely able to target multiple misfolded protein aggregates implicated in serious diseases
AN URGENT NEED
Learn about our commitment to address the significant unmet need of patients with neurodegenerative and systemic amyloidosis diseases
LATEST NEWS
Proclara Biosciences Announces Initiation of NPT189 Clinical Development for Systemic Amyloidoses and Provides Pipeline Update